Xiaohua Jie
Union Hospital
Wuhan, 430022, China
Wuhan, 430022, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
UBE2O Drives Immune Evasion and Radioimmunotherapy Resistance in Lung Cancer by Degrading CDKL1 to Induce PD-L1 Transcription.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: April 19, 2026
PFKFB4 Deubiquitination by USP10 Enhances Fumarate Metabolism to Orchestrate the KDM1A/Rad51 Axis and Confer Radioresistance in Lung Cancer.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: December 19, 2025
Inhibition of protein kinase CK2 remodels the tumor immune microenvironment and sensitizes lung cancer to PD-L1 blockade.
Journal: Experimental hematology & oncology
Published: October 28, 2025
Radiotherapy combined with first-line anti-programmed cell death protein 1 (PD-1) immunotherapy and chemotherapy for patients with advanced non-small cell lung cancer: A bicentric retrospective study.
Journal: Cancer pathogenesis and therapy
Published: December 09, 2024
USP9X-mediated REV1 deubiquitination promotes lung cancer radioresistance via the action of REV1 as a Rad18 molecular scaffold for cystathionine γ-lyase.
Journal: Journal of biomedical science
Published: January 29, 2024
Targeting FBXO22 enhances radiosensitivity in non-small cell lung cancer by inhibiting the FOXM1/Rad51 axis.
Journal: Cell death & disease
Published: August 09, 2023
Targeting diacylglycerol kinase α impairs lung tumorigenesis by inhibiting cyclin D3.
Journal: Thoracic cancer
Published: December 08, 2022
Activation of NLRP3 inflammasome in lung epithelial cells triggers radiation-induced lung injury.
Journal: Respiratory research
Published: November 26, 2022
NLRP6 is required for cancer-derived exosome-modified macrophage M2 polarization and promotes metastasis in small cell lung cancer.
Journal: Cell death & disease
Published: February 24, 2022
Activated amino acid response pathway generates apatinib resistance by reprograming glutamine metabolism in non-small-cell lung cancer.
Journal: Cell death & disease
Published: January 20, 2022
Targeting KDM4C enhances CD8+ T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer.
Journal: Journal for immunotherapy of cancer
Published: January 11, 2022
Last Updated: 09/26/2026